Welcome to our dedicated page for Incannex Healthcare SEC filings (Ticker: ixhl), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Incannex Healthcare's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Incannex Healthcare's regulatory disclosures and financial reporting.
Incannex Healthcare Inc. filed a current report describing a new partnership with the AASM Foundation to support sleep apnea research as its lead drug IHL-42X advances. The company is joining the AASM Foundation’s Corporate Recognition Program and sponsoring a Focused Projects Grant for Junior Investigators on the diagnosis, management, and treatment of sleep apnea, to be awarded in 2026.
The filing highlights recent milestones for IHL-42X, an oral fixed-dose combination of dronabinol and acetazolamide being developed for obstructive sleep apnea, including positive Phase 2 results, FDA Fast Track designation, and progression into the DReAMzz Phase 2 crossover dose-optimisation study ahead of a planned Phase 3 program. Incannex also outlines a broader pipeline that includes IHL-675A for rheumatoid arthritis and PSX-001, a synthetic psilocybin therapy for generalized anxiety disorder.
Incannex Healthcare is highlighting a strong balance sheet following a recently completed financing. The company now holds approximately $75 million in cash with no debt, which management contrasts with a market capitalization of about $46 million, implying a negative enterprise value.
Proceeds from the financing are expected to fund the DReAMzz Phase 2 crossover dose-optimization study for lead candidate IHL-42X in obstructive sleep apnea, while preserving most existing cash for an optimized Phase 3 program. Incannex is also advancing PSX-001 for generalized anxiety disorder under an open FDA IND, and maintains a board-approved share buyback program with remaining capacity. Management views institutional participation in the financing and the company’s cash-rich, debt-free position as external validation of its clinical pipeline and strategy.
Incannex Healthcare Inc. has regained compliance with Nasdaq’s minimum bid price requirement, securing its continued listing on the Nasdaq Capital Market. Nasdaq confirmed the company met the rule after its stock closed at or above $1.00 per share for eleven consecutive business days from February 27 through March 13, 2026.
The company highlights having approximately $75 million in cash and no debt, supporting advancement of its clinical pipeline. Key programs include IHL-42X for obstructive sleep apnea, IHL-675A for inflammatory conditions such as rheumatoid arthritis, and PSX-001 for generalized anxiety disorder.
Incannex Healthcare Inc. is offering 1,997,285 shares of common stock together with accompanying Common Warrants to purchase up to 2,000,000 shares of common stock at a combined unit price of $5.00 per share and accompanying warrant. The offering also includes Pre-Funded Warrants to purchase up to 2,715 shares for eligible investors subject to ownership caps.
The Common Warrants have an exercise price of $6.50 and a five-year term; Pre-Funded Warrants are exercisable for $0.0001 per share. The company estimates net proceeds of approximately $8.9 million, intending to use proceeds for working capital, research and development, and clinical trial expenses. The placement agent is Curvature Securities LLC and delivery is expected on or about March 13, 2026.
Incannex Healthcare Inc. entered into a securities purchase agreement for a registered direct offering to institutional investors. The company will sell 1,997,285 shares of common stock, pre-funded warrants for up to 2,715 additional shares, and common stock warrants to purchase up to 2,000,000 shares.
The securities are priced at a combined purchase price of $5.0 per share and accompanying warrant, or $4.9999 per pre-funded warrant and accompanying warrant, for expected gross proceeds of about $10 million before fees and expenses. The common warrants have a $6.50 exercise price and a five-year term. Warrant exercises are subject to 4.99% or, at the investor’s option, 9.99% ownership caps, and the company agreed to a 60-day restriction on issuing additional equity after closing.
Incannex Healthcare Inc. has ended its at-the-market common stock sales arrangement with Curvature Securities and A.G.P./Alliance Global Partners, which allowed it to sell shares from time to time through these agents. Over the life of this Sales Agreement, Incannex raised approximately $108.4 million in aggregate gross proceeds, and the arrangement was terminable at will by the company with no penalty.
The company also updated its corporate investor presentation, now available via its investor relations website and furnished as an exhibit, and issued a press release describing an enhanced Phase 2 dose-optimisation study, which is provided as another exhibit.
Incannex Healthcare Inc. approved and implemented a 1-for-30 reverse stock split of its common stock. Every 30 shares will be combined into 1 share at 4:01 p.m. Eastern Time on February 26, 2026, with trading on a split-adjusted basis beginning February 27, 2026.
The reverse split will reduce outstanding common shares from approximately 358,329,368 as of February 20, 2026 to about 11,944,313, without changing the total number of authorized shares or the par value. Fractional positions will be rounded up to the next whole share, with no cash paid for fractions.
The company states that the reverse split is intended to increase the per-share trading price of its stock to help regain compliance with Nasdaq’s minimum bid price requirement, while existing shareholders retain the same proportional ownership after the adjustment.
Incannex Healthcare reported no revenue for the quarter ended December 31, 2025, reflecting its status as a clinical-stage biopharmaceutical company. Net loss was $6.5 million for the quarter and $12.9 million for the six months, driven mainly by research and development and higher general and administrative expenses, including increased stock-based compensation.
Cash and cash equivalents rose sharply to $68.9 million from $15.0 million at June 30, 2025, primarily from equity issuances, partially offset by operating cash burn of $13.8 million and $1.5 million of share repurchases under a $20 million buyback program. Management believes existing cash will fund operations for at least 12 months, but the company continues to post sizable losses as it advances key programs, including its IHL-42X Phase 2/3 sleep apnea trial and other Phase 2 assets.
The company reiterates that it remains in a development phase with no product revenue and discloses an ongoing material weakness in internal control over financial reporting related to complex accounting, which it is attempting to remediate through added policies, training and control resources.
Incannex Healthcare Inc. filed a current report to note that, on January 29, 2026, it announced additional appointments to its Clinical Advisory Board. The company states that more details are provided in a press release, which is attached as Exhibit 99.1 and incorporated by reference into the filing.
Incannex Healthcare Inc. filed a current report to note a corporate development related to its PSX-001 program. On January 22, 2026, the company announced it has formed a Clinical Advisory Board to support this program, indicating a step toward organizing expert guidance around its clinical strategy. Details about the advisory board’s members, role, and expected contributions are provided in a press release dated January 22, 2026, which is attached to the report as Exhibit 99.1.